ACC President Comments on the Approval of Weight Loss Drug Qysmia

Contact: Stephanie Abraham,, 202-375-6296

Washington, DC - ACC President William Zoghbi, MD, FACC made the following statement today following the FDA’s approval of the weight-loss drug Qsymia:

“We welcome a new tool, in addition to healthy diet and exercise, to help patients combat obesity. However, it is important to continuously evaluate the overall risks and benefits of any weight-loss aid,” said American College of Cardiology President William Zoghbi, MD, FACC. “Weight-loss drugs have the potential to help manage obesity, which is a major health problem, but it is most important to understand the impact the medications may have on long-term cardiovascular health and patient outcome.”



About the American College of Cardiology
The mission of the American College of Cardiology is to transform cardiovascular care and improve heart health. The College is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers, and bestows credentials upon cardiovascular specialists who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. More information about the association is available online at

< Back to Listings